… , and antiviral efficacy of molnupiravir in the treatment of COVID-19 (ClinicalTrials.gov …
the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 …

… New treatments are needed to reduce the risk of progression of coronavirus disease 2019
(Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against …

… This study shows that three novel oral antiviral drugs (molnupiravir, fluvoxamine and … rates
in COVID-19 patients. In addition, our study showed that the three oral antiviral drugs did not …

… development stage for treating seasonal influenza. With the spread of COVID-19, the …
treatment, and a clinical trial of molnupiravir as an oral therapeutic drug for non-hospitalized …

… Molnupiravir is a newer oral antiviral drug that has recently been tested in COVID-19. We
aim to … of literature to find out the efficacy and safety of molnupiravir in patients with COVID-19. …

… candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with
anti… Molnupiravir is administered orally at doses of 50 mg to 800 mg in each clinical trial. The …

… This study also highlighted that molnupiravir shows antiviral effects because … antiviral efficacy
vs. cytotoxicity) and suggested further clinical studies of molnupiravir for influenza treatment…

… Within 3 days of initiating Molnupiravir oral treatment, the virus load had decreased by an
estimated 88%, compared with an expected reduction in untreated cases of 84%. …

… oral anti-viral drug for the treatment of COVID-19 [4]. The application of this drug on animal
species demonstrated the success of molnupiravir … Based on an oral anti-viral ribonucleoside …

… in emergency settings where the ability to treat a large number of people quickly may be
crucial. … with molnupiravir and what led to its rapid development for the treatment of COVID-19. …